Development of novel anti-myeloma agents with potent bone anabolic actions

• Project/Area Number: 16K11504
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pathobiological dentistry/Dental radiology
• Research Institution: The University of Tokushima
• Principal Investigator: TERAMACHI Jumpei 徳島大学, 大学院医歯薬学研究部(歯学域), 講師 (20515986)
• Project Period (FY): 2016-04-01 – 2020-03-31
• Project Status: Completed (Fiscal Year 2019)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2018: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000); Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: 骨髄腫 / 骨病変 / 破骨細胞 / 骨芽細胞 / TAK1 / 癌と骨病変 / 癌

Outline of Final Research Achievements

Multiple myeloma (MM) has a unique propensity to develop and expand almost exclusively in the bone marrow and generates destructive bone disease. We demonstrate that TGF-β-activated kinase-1 (TAK1) is constitutively overexpressed and phosphorylated in MM cells, and that TAK1 inhibition induce apoptosis in MM cells. TAK1 phosphorylation was also induced along with upregulation of VCAM-1 in bone marrow stromal cells (BMSCs) in cocultures with MM cells, which facilitated MM cell-BMSC adhesion while inducing IL-6 production and receptor RANKL expression by BMSCs. Furthermore, TAK1 inhibition suppressed osteoclastogenesis, and restored osteoblastic differentiation suppressed by MM. Treatment with the TAK1 inhibitor suppressed MM growth and prevented bone destruction and loss in mouse MM models. Therefore, TAK1 inhibition may be a therapeutic option targeting not only MM cells but also the skewed bone marrow microenvironment in MM.

Academic Significance and Societal Importance of the Research Achievements

本研究は、現在も尚重大な臨床課題として残されている腫瘍細胞と骨髄微小環境との細胞間相互作用がもたらす薬剤耐性を克服し、骨破壊性悪性腫瘍における骨形成の回復・骨再生という患者QOLの改善に向けた新規治療法の開発に繋がる点に特色と意義がある。TAK1は骨髄腫だけでなく他の種々の悪性腫瘍においても標的分子となりうることが考えられ、TAK1を標的とした治療法の開発は癌全般の新規治療法の開発にも波及することが期待できる。TAK1の抑制は直接的に破骨細胞分化を抑制し、骨芽細胞分化を惹起させるため腫瘍性骨喪失のみならず炎症性骨喪失、薬剤性骨喪失に対する新規骨形成療法の開発への新たな道を拓くことが予想される。

Research Products

• [Journal Article] Osteoclast-derived IGF1 is required for pagetic lesion formation in vivo (2020)
  • Author(s): Miyagawa Kazuaki、Ohata Yasuhisa、Delgado-Calle Jesus、Teramachi Jumpei、Zhou Hua、Dempster David D.、Subler Mark A.、Windle Jolene J.、Chirgwin John M.、Roodman G. David、Kurihara Noriyoshi
  • Journal Title: JCI Insight Volume: 5 Issue: 6
  • DOI: 10.1172/jci.insight.133113
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma. (2020)
  • Author(s): 2. Teramachi J, Tenshin H, Hiasa M, Oda A, Bat-Erdene A, Harada T, Nakamura S, Ashtar M, Shimizu S, Iwasa M, Sogabe K, Oura M, Fujii S, Kagawa K, Miki H, Endo I, Haneji T, Matsumoto T, Abe M.
  • Journal Title: Haematologica Volume: haematol.2019 Issue: 5 Pages: 1401-1413
  • DOI: 10.3324/haematol.2019.234476
  • NAID: 120007180361
  • Peer Reviewed / Open Access
• [Journal Article] The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat. (2020)
  • Author(s): 1. Ashtar M, Tenshin H, Teramachi J, Bat-Erdene A, Hiasa M, Oda A, Tanimoto K, Shimizu S, Higa Y, Harada T, Oura M, Sogabe K, Nakamura S, Fujii S, Sumitani R, Miki H, Udaka K, Takahashi M, Kagawa K, Endo I, Tanaka E, Matsumoto T, Abe M.
  • Journal Title: Cancers (Basel) Volume: 12 Issue: 4 Pages: 929-929
  • DOI: 10.3390/cancers12040929
  • NAID: 120006894611
  • Peer Reviewed / Open Access
• [Journal Article] PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ. (2019)
  • Author(s): Iwasa Masami、Harada Takeshi、Oda Asuka、Bat-Erdene Ariunzaya、Teramachi Jumpei、Tenshin Hirofumi、Ashtar Mohannad、Oura Masahiro、Sogabe Kimiko、Udaka Kengo、Fujii Shiro、Nakamura Shingen、Miki Hirokazu、Kagawa Kumiko、Ozaki Shuji、Abe Masahiro
  • Journal Title: Oncotarget Volume: 10 Issue: 20 Pages: 1903-1917
  • DOI: 10.18632/oncotarget.26726
  • Peer Reviewed / Open Access
• [Journal Article] Persistent activation of calcium-sensing receptor suppresses bone turnover, increases microcracks and decreases bone strength (2019)
  • Author(s): Bingzi Dong, Itsuro Endo, Yukiyo Ohnishi, Yukari Mitsui, Kiyoe Kurahashi, Mai Kanai, Masahiro Hiasa, Jumpei Teramachi, Hirofumi Tenshin, Seiji Fukumoto, Masahiro Abe, Toshio Matsumoto.
  • Journal Title: JBMR Plus Volume: inpress Issue: 7
  • DOI: 10.1002/jbm4.10182
  • Peer Reviewed / Open Access
• [Journal Article] Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA (2018)
  • Author(s): Bat-Erdene Ariunzaya、Nakamura Shingen、Oda Asuka、Iwasa Masami、Teramachi Jumpei、Ashtar Mohannad、Harada Takeshi、Miki Hirokazu、Tenshin Hirofumi、Hiasa Masahiro、Fujii Shiro、Sogabe Kimiko、Oura Masahiro、Udaka Kengo、Kagawa Kumiko、Yoshida Sumiko、Aihara Ken-ichi、Kurahashi Kiyoe、Endo Itsuro、Abe Masahiro
  • Journal Title: British Journal of Haematology Volume: 印刷中 Issue: 5 Pages: 969-974
  • DOI: 10.1111/bjh.15673
  • Peer Reviewed / Open Access
• [Journal Article] Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity. (2018)
  • Author(s): Fujii S, Nakamura S, Oda A, Miki H, Tenshin H, Teramachi J, Hiasa M, Bat-Erdene A, Maeda Y, Oura M, Takahashi M, Iwasa M, Endo I, Yoshida S, Aihara KI, Kurahashi K, Harada T, Kagawa K, Nakao M, Sano S, Abe M.
  • Journal Title: British Journal of Haematology Volume: 180(2) Issue: 2 Pages: 246-258
  • DOI: 10.1111/bjh.15033
  • Peer Reviewed
• [Journal Article] Effective impairment of myeloma cells and their progenitors by hyperthermia. (2018)
  • Author(s): Hirokazu Miki, Shingen Nakamura, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, M. Hiasa, A. Bat-Erdene, Y. Maeda, M. Oura, M. Takahashi, M. Iwasa, T. Harada, S. Fujii, K. Kurahashi, S. Yoshida, K. Kagawa, I. Endo, K. Aihara, M. Ikuo, K. Itoh, Koichiro Hayashi, Michihiro Nakamura, Masahiro Abe
  • Journal Title: Oncotarget Volume: 9 Issue: 12 Pages: 10307-10316
  • DOI: 10.18632/oncotarget.23121
  • NAID: 120006576960
  • Peer Reviewed
• [Journal Article] Reduction of protein phosphatase 2A Cα promotes in vivo bone formation and adipocyte differentiation (2017)
  • Author(s): Yoshida Kaya、Teramachi Jumpei、Uchibe Kenta、Ikegame Mika、Qiu Lihong、Yang Di、Okamura Hirohiko
  • Journal Title: Molecular and Cellular Endocrinology Volume: 印刷中 Pages: 251-258
  • DOI: 10.1016/j.mce.2017.11.005
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects (2017)
  • Author(s): Tenshin Hirofumi、Teramachi Jumpei、Tanaka Eiji、Matsumoto Toshio、Abe Masahiro (他16人中2番目）
  • Journal Title: Blood Advances Volume: 1 Issue: 24 Pages: 2124-2137
  • DOI: 10.1182/bloodadvances.2017008813
  • Peer Reviewed / Open Access
• [Journal Article] Role of protein phosphatase 2A in osteoblast differentiation and function. (2017)
  • Author(s): Okamura H, Yoshida K, Morimoto H, Teramachi J, Ochiai K, Haneji T, Yamamoto A.
  • Journal Title: J Clin Med Volume: 6(3) Issue: 3 Pages: 23-23
  • DOI: 10.3390/jcm6030023
  • Peer Reviewed / Open Access
• [Journal Article] Involvement of interleukin 23 induced by Porphyromonas endodontalis lipopolysaccharide in osteoclastogenesis. (2017)
  • Author(s): Ma N, Yang D, Okamura H, Teramachi J, Hasegawa T, Qiu L, Haneji T.
  • Journal Title: Molecular Medicine Reports Volume: 15 Issue: 2 Pages: 559-566
  • DOI: 10.3892/mmr.2016.6041
  • Peer Reviewed
• [Journal Article] Expansion of Th1-like Vγ9Vδ2T cells by new generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid. (2017)
  • Author(s): 2. Harada T, Miki H, Cui Q, Oda A, Amachi R, Teramachi J, Bat-Erdene A, Sogabe K, Iwasa M, Fujii S, Nakamura S, Kagawa K, Yoshida S, Endo I, Aihara K, Ozaki S, Matsumoto T, Abe M.
  • Journal Title: Leukemia Volume: 31 Issue: 1 Pages: 258-262
  • DOI: 10.1038/leu.2016.273
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma. (2017)
  • Author(s): Teramachi J, Hiasa M, Oda A, Harada T, Nakamura S, Amachi R, Tenshin H, Iwasa M, Fujii S, Kagawa K, Miki H, Kurahashi K, Yoshida S, Endo I, Haneji T, Matsumoto T, Abe M
  • Journal Title: Br J Haematol Volume: E-pub Issue: 4 Pages: 581-585
  • DOI: 10.1111/bjh.14388
  • NAID: 120006549655
  • Peer Reviewed
• [Journal Article] PKR regulates LPS-induced osteoclast formation and bone destruction in vitro and in vivo. (2017)
  • Author(s): Teramachi J, Inagaki Y, Shinohara H, Okamura H, Yang D, Ochiai K, Baba R, Morimoto H, Nagata T, Haneji T.
  • Journal Title: Oral Dis. Volume: 23(2) Issue: 2 Pages: 181-8
  • DOI: 10.1111/odi.12592
  • Peer Reviewed / Open Access
• [Journal Article] Histone demethylase Jmjd3 regulates osteoblast differentiation through targeting anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bim (2016)
  • Author(s): Yang D, Okamura H, Teramachi J, Haneji T
  • Journal Title: BBA Molecular Cell Research Volume: 1863 Issue: 4 Pages: 650-659
  • DOI: 10.1016/j.bbamcr.2016.01.006
  • Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
• [Journal Article] Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease (2016)
  • Author(s): Teramachi J, Nagata Y, Mohammad K, Inagaki Y, Ohata Y, Guise T, Michou L, Brown JP, Windle JJ, Kurihara N, Roodman GD
  • Journal Title: Journal of Clinical Investigation Volume: 126 Issue: 3 Pages: 1012-1022
  • DOI: 10.1172/jci82012
  • Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
• [Journal Article] Protein phosphatase 2A Cα regulates proliferation, migration, and metastasis of osteosarcoma cells. (2016)
  • Author(s): Yang D, Okamura H, Morimoto H, Teramachi J, Haneji T.
  • Journal Title: Lab Invest. Volume: 96(10) Issue: 10 Pages: 1050-62
  • DOI: 10.1038/labinvest.2016.82
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration. (2016)
  • Author(s): Amachi R, Hiasa M, Teramachi J, Harada T, Oda A, Nakamura S, Hanson D, Watanabe K, Fujii S, Miki H, Kagawa K, Iwasa M, Endo I, Kondo T, Yoshida S, Aihara KI, Kurahashi K, Kuroda Y, Horikawa H, Tanaka E, Matsumoto T, Abe M
  • Journal Title: Oncotarget Volume: 7 Issue: 43 Pages: 70447-70461
  • DOI: 10.18632/oncotarget.11927
  • NAID: 120006576954
  • Peer Reviewed / Open Access
• [Journal Article] Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors (2016)
  • Author(s): Bat-Erdene A, Miki H, Oda A, Nakamura S, Teramachi J, Amachi R, Tenshin H, Hiasa M, Iwasa M, Harada T, Fujii S, Sogabe K, Kagawa K, Yoshida S, Endo I, Aihara K, Abe M.
  • Journal Title: Oncotarget Volume: 7 Issue: 48 Pages: 79064-79075
  • DOI: 10.18632/oncotarget.12594
  • Peer Reviewed / Open Access
• [Presentation] 多発性骨髄腫の骨破壊と腫瘍進展の分子病態の解明と新規治療法の開発 (2019)
  • Author(s): 寺町順平
  • Organizer: 第37回日本骨代謝学会
  • Invited
• [Presentation] Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM. (2019)
  • Author(s): Teramachi J, Miyagawa K, Jesus DC, Windle JJ, Kurihara N, Roodman GD.
  • Organizer: American Society of Hematology 2019 Annual Meeting
  • Int'l Joint Research
• [Presentation] A progressive auto-amplification loop in TAK1 expression and activation in MM cells. (2019)
  • Author(s): Teramachi J, Shimizu S, Harada T, Tenshin H, Oda A, Bat-Erdene A, Hiasa M, Tanimoto K, Endo I, Haneji T, Matsumoto T, Tanaka E, Abe M.
  • Organizer: International Myeloma Workshop 2019
  • Int'l Joint Research
• [Presentation] A progressive auto-amplification loop in TAK1 expression and activation in MM cells. (2019)
  • Author(s): Teramachi J, Shimizu S, Tenshin H, Bat-Erdene A, Hiasa M, Oda A, Harada T, Ashter M, Tanimoto K, Endo I, Matsumoto T, Tanaka E, Abe M.
  • Organizer: American Society for Bone and Mineral Research 2019 Annual Meeting
  • Int'l Joint Research
• [Presentation] 骨髄腫細胞における脱リン酸化酵素PP2Aの活性抑制機構 (2019)
  • Author(s): 寺町順平
  • Organizer: 令和元年度がん研究開発費（大江班・骨髄腫小班）・AMED（丸山班）合同班会議
• [Presentation] 骨髄腫細胞における脱リン酸化酵素活性制御異常と TAK１を介する生存シグナルの活性化 (2019)
  • Author(s): 寺町順平
  • Organizer: 日本解剖学会第73回中国・四国支部学術集会
• [Presentation] 骨髄腫におけるTAK1の発現および活性化の自己増幅 (2019)
  • Author(s): 3.寺町 順平, 清水 宗, 天真 寛文, Ariunzaya Baterdene, 小田 明日香, 日浅 雅博, 原田 武志, 谷本 幸多朗, Mohannad Ashter, 田中 栄二, 安倍 正博
  • Organizer: 第82回日本血液学会学術集会
• [Presentation] TAK1阻害は腫瘍と微小環境との相互作用を遮断し腫瘍進展・骨破壊病変形成を抑制する (2019)
  • Author(s): 寺町順平, 天真寛文, 日浅雅博, 安倍正博
  • Organizer: 第124回日本解剖学会総会・全国学術集会
• [Presentation] Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction (2018)
  • Author(s): Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Akihito Yamamoto, Tatsuji Haneji, Toshio Matsumoto, Masahiro Abe
  • Organizer: 8th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone and other Musculoskeletal Diseases and Cancer and Bone Society 2018 Meeting
  • Int'l Joint Research
• [Presentation] Disruption of a progressive vicious cycle between myeloma tumor growth and bone destruction by TAK1 inhibition (2018)
  • Author(s): Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto, Masahiro Abe
  • Organizer: American Society for Bone and Mineral Research 2018 Annual Meeting
  • Int'l Joint Research
• [Presentation] TAK1阻害は骨髄腫細胞と骨髄相互作用を抑制し、腫瘍進展と骨病変形成を抑制する (2018)
  • Author(s): 寺町順平, 天真寛文, 日浅雅博, 遠藤逸朗, 松本俊夫, 安倍正博
  • Organizer: 第36回日本骨代謝学会学術集会
• [Presentation] Mechanisms of TAK1 over-activation in myeloma cells and TAK1-mediated myeloma growth and bone destruction (2018)
  • Author(s): Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Masami Iwasa, Shiro Fujii, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Masahiro Oura, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto, Masahiro Abe
  • Organizer: 第80回日本血液学会学術集会
• [Presentation] 骨髄腫特異的抗腫瘍活性と骨再生をもたらす新規分子標的薬の開発 (2018)
  • Author(s): 寺町順平, 天真寛文, 日浅雅博, 遠藤逸朗, 松本俊夫, 安倍正博
  • Organizer: 2018 先端医学交流セミナー
  • Invited
• [Presentation] 骨形成誘導活性を有する新規抗骨髄腫薬の開発 (2017)
  • Author(s): 寺町順平、日浅雅博、安倍正博
  • Organizer: 第42回日本骨髄腫学会学術大会
  • Invited
• [Presentation] Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction (2017)
  • Author(s): Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Akihito Yamamoto, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe
  • Organizer: Cancer and Bone Society Conference 2017
  • Int'l Joint Research
• [Presentation] Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction (2017)
  • Author(s): Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Akihito Yamamoto, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe
  • Organizer: International Society for Experimental Hematology 46th Annual Scientific Meeting
  • Int'l Joint Research
• [Presentation] Development of novel anti-myeloma agents with potent bone anabolic actions (2017)
  • Author(s): Jumpei Teramachi, Masahiro Hiasa, Masahiro Abe
  • Organizer: 14th Bone Biology Forum
  • Int'l Joint Research / Invited
• [Presentation] 骨髄腫腫瘍進展抑制と骨形成誘導活性を有する新規薬剤の開発 (2017)
  • Author(s): 寺町順平
  • Organizer: 第35回日本骨代謝学会学術集会
  • Invited
• [Presentation] 骨破壊性腫瘍におけるカテプシンK阻害剤の骨形成誘導作用 (2017)
  • Author(s): 寺町順平
  • Organizer: 第59回歯科基礎医学会学術大会
• [Presentation] Disruption of myeloma cell-bone marrow interaction by TAK-1 inhibition (2017)
  • Author(s): 寺町順平, 日浅雅博, 小田明日香, 天真寛文, 天知良太, 原田武志, 中村 信元, 岩佐 昌美, 大浦雅博, 前田悠作, 藤井志朗, 賀川 久美子, 三木 浩和, 遠藤 逸朗, 山本朗仁, 松本 俊夫, 安倍 正博
  • Organizer: 第79回日本血液学会学術集会
• [Presentation] TAK1 inhibition impairs myeloma cell-bone marrow interaction to reduce myeloma tumor growth and bone destruction (2017)
  • Author(s): Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Akihito Yamamoto, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe
  • Organizer: American Society for Bone and Mineral Research 2017 Annual Meeting
  • Int'l Joint Research
• [Presentation] 骨破壊性腫瘍におけるカテプシンK阻害剤の骨形成誘導作用 (2017)
  • Author(s): 寺町順平
  • Organizer: 日本解剖学会 第73回中国・四国支部学術集会
• [Presentation] 骨髄腫の腫瘍進展と骨破壊病変形成におけるTAK1の枢軸的な役割 (2016)
  • Author(s): 寺町 順平, 日浅 雅博, 岡村 裕彦, 安倍 正博, 羽地 達次
  • Organizer: 日本解剖学会第71回中国・四国支部学術集会
  • Place of Presentation: 岡山大学(岡山県・岡山市）
  • Year and Date: 2016-10-22
• [Presentation] TAK-1 inhibition disrupts Pim-2-associated and Pim-2-independent key signaling pathways to effectively suppress tumor growth and restore bone formation in myeloma (2016)
  • Author(s): Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kiyoe Kurahashi, Takeshi Kondo, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe
  • Organizer: 第78回 日本血液学会学術集会
  • Place of Presentation: パシフィコ横浜（神奈川県・横浜市）
  • Year and Date: 2016-10-13
• [Presentation] TAK-1 inhibition disrupts Pim-2-associated and Pim-2-independent key signaling pathways to effectively suppress tumor growth and restore bone formation in myeloma (2016)
  • Author(s): Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kiyoe Kurahashi, Takeshi Kondo, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe
  • Organizer: American Society for Bone and Mineral Research 2016 Annual Meeting
  • Place of Presentation: アトランタ・アメリカ合衆国
  • Year and Date: 2016-09-16
  • Int'l Joint Research
• [Presentation] TAK-1阻害による腫瘍進展の抑制と骨病変の改善効果 (2016)
  • Author(s): 寺町 順平, 岡村 裕彦, 羽地 達次
  • Organizer: 第58回歯科基礎医学会学術大会
  • Place of Presentation: 札幌コンベンションセンター（北海道・札幌市）
  • Year and Date: 2016-08-24
• [Presentation] 骨髄腫腫瘍進展と骨破壊病変形成におけるTAK1-Pim-2経路の役割 (2016)
  • Author(s): 寺町 順平, 日浅 雅博, 小田 明日香, 天真 寛文, 天知 良太, 原田 武志, 渡邉 佳一郎, 中村 信元, 三木 浩和, 遠藤 逸朗, 羽地 達次, 松本 俊夫, 安倍 正博
  • Organizer: 第34回日本骨代謝学会学術集会
  • Place of Presentation: 大阪国際会議場（大阪府・大阪市）
  • Year and Date: 2016-07-20
• [Presentation] Therapeutic impact of TAK-1 inhibition on tumor growth and bone destruction in myeloma (2016)
  • Author(s): Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio
  • Organizer: 21st Congress European Hematology Association
  • Place of Presentation: コペンハーゲン・デンマーク
  • Year and Date: 2016-06-09
  • Int'l Joint Research
• [Presentation] Pim-2は骨髄腫における破骨細胞形成促進の 必須媒介因子である (2016)
  • Author(s): 寺町 順平, 日浅 雅博, 小田 明日香, 原田 武志, 天真 寛文, 中村 信元, 天知 良太, 藤井 志朗, 渡邉 佳一郎, 賀川 久美子, 三木 浩和, 遠藤 逸朗, 羽地 達次, 松本 俊夫, 安倍 正博
  • Organizer: 第41回日本骨髄腫学会学術集会
  • Place of Presentation: あわぎんホール（徳島県・徳島市）
  • Year and Date: 2016-05-28
• [Presentation] TAK-1阻害による骨髄腫腫瘍進展の抑制と骨病変の再生効果 (2016)
  • Author(s): 寺町 順平
  • Organizer: 第41回日本骨髄腫学会学術集会
  • Place of Presentation: あわぎんホール（徳島県・徳島市）
  • Year and Date: 2016-05-28
  • Invited
• [Book] 多発性骨髄腫学 (2016)
  • Author(s): 寺町 順平, 安倍 正博
  • Total Pages: 591
  • Publisher: 日本臨牀社
• [Patent(Industrial Property Rights)] 新規イノン化合物及びその用途 (2019)
  • Inventor(s): 徳島大学
  • Industrial Property Rights Holder: 徳島大学
  • Industrial Property Rights Type: 特許
  • Filing Date: 2019
  • Acquisition Date: 2019
  • Overseas
• [Patent(Industrial Property Rights)] 新規イノン化合物及びその用途 (2018)
  • Inventor(s): 徳島大学
  • Industrial Property Rights Holder: 徳島大学
  • Industrial Property Rights Type: 特許
  • Filing Date: 2018